Among compensated ambulatory patients with HFpEF in Japan, 17.6% met the domestic insurance eligibility criteria for obesity treatment with GLP-1RA and GIP/GLP-1RA.
Observational (n=3,706)
Yes
What is the prevalence of HFpEF patients in Japan who meet obesity-related eligibility criteria for GLP-1RA and GIP/GLP-1RA?
Background: The prevalence of patients with heart failure with preserved ejection fraction (HFpEF) who meet the insurance eligibility criteria in Japan for obesity treatment with the glucagon-like peptide-1 receptor agonist (GLP-1RA), and the dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist (GIP/GLP-1RA) remains unclear.
Nishikawa et al. (Thu,) conducted a observational in Heart failure with preserved ejection fraction (HFpEF) (n=3,706). Eligibility for GLP-1RA and GIP/GLP-1RA vs. Non-eligible patients was evaluated on Prevalence of eligibility for GLP-1RA and GIP/GLP-1RA. Among compensated ambulatory patients with HFpEF in Japan, 17.6% met the domestic insurance eligibility criteria for obesity treatment with GLP-1RA and GIP/GLP-1RA.